Literature DB >> 12668803

Lung cancer. 4: chemotherapy for non-small cell lung cancer: the end of the beginning.

M Cullen1.   

Abstract

The development of chemotherapy for NSCLC over the last 20 years is reviewed, particularly with regard to its palliative effects. New "fourth generation" agents designed to inhibit specific biological pathways thought to be crucial to tumour growth give cause for optimism in the future treatment of NSCLC.

Entities:  

Mesh：

Year:  2003        PMID： 12668803      PMCID： PMC1746634          DOI： 10.1136/thorax.58.4.352

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  24 in total

1.  'Best supportive care' has had its day.

Authors:  M Cullen
Journal:  Lancet Oncol       Date:  2001-03       Impact factor: 41.316

2.  Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma.

Authors:  T Le Chevalier; R Arriagada; M Tarayre; M J Lacombe-Terrier; A Laplanche; E Quoix; P Ruffie; M Martin; J Y Douillard
Journal:  J Natl Cancer Inst       Date:  1992-01-01       Impact factor: 13.506

3.  The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer.

Authors:  L J Billingham; M H Cullen
Journal:  Ann Oncol       Date:  2001-12       Impact factor: 32.976

4.  Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

Authors:  F V Fossella; R DeVore; R N Kerr; J Crawford; R R Natale; F Dunphy; L Kalman; V Miller; J S Lee; M Moore; D Gandara; D Karp; E Vokes; M Kris; Y Kim; F Gamza; L Hammershaimb
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

5.  Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.

Authors:  T Le Chevalier; R Arriagada; E Quoix; P Ruffie; M Martin; M Tarayre; M J Lacombe-Terrier; J Y Douillard; A Laplanche
Journal:  J Natl Cancer Inst       Date:  1991-03-20       Impact factor: 13.506

6.  A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

Authors:  J A Roth; F Fossella; R Komaki; M B Ryan; J B Putnam; J S Lee; H Dhingra; L De Caro; M Chasen; M McGavran
Journal:  J Natl Cancer Inst       Date:  1994-05-04       Impact factor: 13.506

7.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

Authors:  R Rosell; J Gómez-Codina; C Camps; J Maestre; J Padille; A Cantó; J L Mate; S Li; J Roig; A Olazábal
Journal:  N Engl J Med       Date:  1994-01-20       Impact factor: 91.245

8.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.

Authors:  E Rapp; J L Pater; A Willan; Y Cormier; N Murray; W K Evans; D I Hodson; D A Clark; R Feld; A M Arnold
Journal:  J Clin Oncol       Date:  1988-04       Impact factor: 44.544

9.  Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.

Authors:  H Anderson; P Hopwood; R J Stephens; N Thatcher; B Cottier; M Nicholson; R Milroy; T S Maughan; S J Falk; M G Bond; P A Burt; C K Connolly; M B McIllmurray; J Carmichael
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

10.  Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.

Authors:  P A Ellis; I E Smith; J R Hardy; M C Nicolson; D C Talbot; S E Ashley; K Priest
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640
View more
  2 in total

Review 1.  Tuberculosis: mother of thoracic surgery then and now, past and prospectives: a review.

Authors:  Tamas F Molnar
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

2.  Systemic anticancer therapy (SACT) for lung cancer and its potential for interactions with other medicines.

Authors:  Ryan Panchal
Journal:  Ecancermedicalscience       Date:  2017-09-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.